Strategic Partnerships RareMoon has announced a strategic partnership with Franklin Biolabs to offer joint consulting packages for preclinical-to-clinical transitions. This signals a willingness to collaborate with CROs and early-stage developers, presenting a near-term opportunity to position regulatory services as the bridge between preclinical and clinical programs.

Orphan & Advanced Therapies Focus The company specializes exclusively in orphan drugs and advanced therapies, including cell and gene therapies. This specialization aligns with high-value, high-need programs and ongoing market trends, suggesting sales potential with startups and sponsors advancing rare disease programs seeking regulatory strategy and dossier support.

Regulatory Readiness Across Stages RareMoon supports sponsors from IND preparation through accelerated pathways, designation planning, and regulatory operations. This end-to-end capability opens conversations with teams at multiple maturation points, including those planning accelerated approvals or designations who may require ongoing regulatory and clinical operations support.

Small Firm, High Impact With a lean team and revenue in the lower mid-range, RareMoon offers focused, high-touch regulatory affairs services. There is an opportunity to upsell larger programs or add-on fractional services to biotech and rare disease companies looking for expert regulatory leadership without engaging a large CRO.

Growth Momentum Recent press indicates a publicized expansion through a joint offering with a notable CRO partner, signaling momentum and credibility. This can be leveraged to target sponsor organizations seeking validated regulatory pathways and demonstrated collaborative execution for preclinical-to-clinical milestones.